BioCryst Pharmaceuticals News Releases http://ir.biocryst.com/ BioCryst Pharmaceuticals News Releases en BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial http://ir.biocryst.com/news-releases/news-release-details/biocrysts-oral-bcx7353-meets-primary-endpoint-phase-3-apex-2 NDA filing on-track for Q4 2019 RESEARCH TRIANGLE PARK, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the randomized (n=121), double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for the prevention of Tue, 21 May 2019 07:00:04 -0400 BioCryst Pharmaceuticals News Releases 19971 BioCryst to Present at Bank of America Merrill Lynch Health Care Conference http://ir.biocryst.com/news-releases/news-release-details/biocryst-present-bank-america-merrill-lynch-health-care RESEARCH TRIANGLE PARK, N.C., May 10, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 15, 2019 at 1:00 p.m. ET. Fri, 10 May 2019 06:59:53 -0400 BioCryst Pharmaceuticals News Releases 19936 BioCryst Completes Phase 1 Clinical Trial of Galidesivir http://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-phase-1-clinical-trial-galidesivir RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. Thu, 09 May 2019 16:14:50 -0400 BioCryst Pharmaceuticals News Releases 19921 BioCryst Reports First Quarter 2019 Financial Results http://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-first-quarter-2019-financial-results —Phase 3 APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Phase 3 ZENITH-2 trial of oral BCX7353 for acute treatment of HAE attacks to commence this summer— —Phase 1 trial of oral Factor D inhibitor, Wed, 08 May 2019 07:00:04 -0400 BioCryst Pharmaceuticals News Releases 19906 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-inducement-grants-under-nasdaq-listing-rule RESEARCH TRIANGLE PARK, N.C., May 06, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 141,224 shares of BioCryst common stock Mon, 06 May 2019 07:00:14 -0400 BioCryst Pharmaceuticals News Releases 19881 BioCryst to Report First Quarter 2019 Financial Results on May 8 http://ir.biocryst.com/news-releases/news-release-details/biocryst-report-first-quarter-2019-financial-results-may-8 RESEARCH TRIANGLE PARK, N.C. , April 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial results on Wednesday, May 8, 2019 . BioCryst management will host a conference call and webcast at 8:30 a.m. Wed, 24 Apr 2019 07:00:00 -0400 BioCryst Pharmaceuticals News Releases 19866 BioCryst to Present at Upcoming Investor Conferences http://ir.biocryst.com/news-releases/news-release-details/biocryst-present-upcoming-investor-conferences-0 RESEARCH TRIANGLE PARK, N.C., April 01, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8, 2019 at 4:30 a.m. Mon, 01 Apr 2019 07:00:22 -0400 BioCryst Pharmaceuticals News Releases 19811 BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-fourth-quarter-and-full-year-2018-financial —APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Full ZENITH-1 results confirm safety and efficacy profile of oral 750 mg BCX7353 for upcoming Phase 3 trial in acute treatment of HAE— —Oral Factor D Mon, 04 Mar 2019 07:02:11 -0500 BioCryst Pharmaceuticals News Releases 19771 BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development http://ir.biocryst.com/news-releases/news-release-details/biocryst-advancing-bcx9930-oral-factor-d-inhibitor-complement —BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervous system — —Patients currently limited to intravenous (IV) infusion therapy, or no therapy — —Phase 1 Mon, 04 Mar 2019 07:00:40 -0500 BioCryst Pharmaceuticals News Releases 19766 BioCryst to Present at Barclays Global Healthcare Conference http://ir.biocryst.com/news-releases/news-release-details/biocryst-present-barclays-global-healthcare-conference RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare Conference in Miami Beach, Florida on Tuesday, March 12, 2019 at 8:00 a.m. ET. Thu, 28 Feb 2019 07:00:11 -0500 BioCryst Pharmaceuticals News Releases 19756